ASH Clinical News April 2016 | Page 72

AT CSL BEHRING, WE’RE WORKING
TO UNVEIL INNOVATIVE SOLUTIONS
IN HEMOPHILIA A
A century of experience…a future of discovery
Continuing the legacy of Emil von Behring, recipient of the first Nobel Prize
in medicine, CSL Behring specializes in developing biotherapeutics
for serious and rare conditions, including hemophilia A.

Biotherapies for Life® is a registered trademark of CSL Behring LLC.
©2016 CSL Behring LLC 1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USA www.CSLBehring-us.com AFS16-02-0001 03/2016